Meningococcal B Vaccine (Bexsero)

Bexsero protects against Neisseria meningitidis serogroup B, the most common cause of bacterial meningitis in Europe and increasingly in India. Recommended for students in dormitories and those with complement deficiencies.

The Meningococcal B Vaccine (Bexsero) is recommended for 2 months and above. It falls under the Adolescent vaccine category. Consult your doctor to confirm if this vaccine is right for you based on your health history and existing immunity.

The Meningococcal B Vaccine (Bexsero) has an efficacy of 73–88% effective against invasive meningococcal B disease. This means it provides significant protection against Meningococcal B meningitis and Septicemia. Efficacy may vary based on age, health status, and the specific strain encountered.

Common side effects include: Injection site pain; fever; headache; myalgia. These are typically mild and resolve within 1–3 days. Serious allergic reactions are rare — if you experience difficulty breathing, hives, or rapid heartbeat after vaccination, seek emergency care immediately.

The Meningococcal B Vaccine (Bexsero) should be avoided by: Severe allergic reaction to prior dose or vaccine components.. Always inform your healthcare provider of your full medical history before vaccination.

The Meningococcal B Vaccine (Bexsero) typically costs ₹6,000–₹8,000 per dose in India. Government health centres may offer it free or at subsidised prices for eligible age groups. Private hospitals and clinics may charge differently. Additional fees may apply for administration.